Agents for high-risk patients
| Anti-Pseudomonal β-lactams | Aminoglycosides | Anti-ESBL producers |
| Imipenem Meropenem Cefepime Piperacillin/Tazobactam Ceftazidime Ceftolozane–Tazobactam# | Amikacin (first line) Gentamicin Tobramycin | Carbapenem (first line) Cefepime Piperacillin/Tazobactam Ceftazidime–Avibactam# |
ESBL: extended spectrum β-lactamase. #: these two antibiotics were not commercialised during the guideline revision period and were not mentioned in the guidelines.